Yifan Huang
China Three Gorges University · 130 works · 6,946 citations · h-index 26
Top works
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
- Hochberg's Step-Up Method: Cutting Corners Off Holm's Step-Down Method
- 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation
- To permute or not to permute
- Maternal High Folic Acid Supplement Promotes Glucose Intolerance and Insulin Resistance in Male Mouse Offspring Fed a High-Fat Diet
- Association of Childhood and Adolescent Anthropometric Factors, Physical Activity, and Diet with Adult Mammographic Breast Density
- Association Between Polymorphisms in HSD3B1 and UGT2B17 and Prostate Cancer Risk
- Lipoprotein lipase links vitamin D, insulin resistance, and type 2 diabetes: a cross-sectional epidemiological study
- Association of Single Nucleotide Polymorphisms in Glycosylation Genes with Risk of Epithelial Ovarian Cancer
- Safety and Efficacy of Menin Inhibition in Patients (Pts) with MLL-Rearranged and NPM1 Mutant Acute Leukemia: A Phase (Ph) 1, First-in-Human Study of SNDX-5613 (AUGMENT 101)
- Voriconazole provides effective prophylaxis for invasive fungal infection in patients receiving glucocorticoid therapy for GVHD
- Performance of Amplified DNA in an Illumina GoldenGate BeadArray Assay
- Effects of cytochrome P450 (CYP3A4 and CYP2C19) inhibition and induction on the exposure of selumetinib, a MEK1/2 inhibitor, in healthy subjects: results from two clinical trials
- Calcium-deficiency assessment and biomarker identification by an integrated urinary metabonomics analysis
- Durvalumab in ≥ 3rd-line EGFR mutant/ALK+, locally advanced or metastatic NSCLC: Results from the phase 2 ATLANTIC study
- The Immune Factors Involved in the Pathogenesis, Diagnosis, and Treatment of Sjogren's Syndrome
- Factors associated with acute oral mucosal reaction induced by radiotherapy in head and neck squamous cell carcinoma
- A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma
- PL04a.03: Durvalumab in ≥3rd-Line Locally Advanced or Metastatic, EGFR/ALK Wild-Type NSCLC: Results from the Phase 2 ATLANTIC Study